ReviewFrontiers in endocrinology2026
Postprandial glucose management of people with insulin-treated diabetes.
Review in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes is a highly prevalent, chronic condition requiring complex treatment strategies and close monitoring. Achievement of optimal glucose management reduces vascular complications of diabetes and the long-term burden of the disease. Attenuation of postprandial rise in glucose is a critical component of overall glycemic management and often the most difficult for people with insulin-treated diabetes to achieve. While postprandial glucose (PPG) elevations are a consequence of insufficient endogenous insulin secretion or exogenous insulin dose to cover ingested carbohydrates, a mismatch between the absorption of nutrients and peak insulin concentration is also a key factor in managing PPG. Type 2 diabetes is characterized by loss of first-phase insulin secretion, resulting in elevations in PPG and prolongation of hyperglycemia after eating. In type 1 diabetes and other forms of insulin-requiring diabetes, insulin administration must match carbohydrate and other nutrient intake in both quantity and timing. Continuous glucose monitoring (CGM) has provided insights into glucose patterns and the effectiveness of diabetes therapies in managing glucose levels at all times of the day. When CGM is used with an automated insulin delivery pump or connected insulin pen, prandial insulin dosing can be analyzed for more effective coaching and education. Based on the 2026 American Diabetes Association Standards of Care guidelines, delivery devices and method of insulin administration should be assessed regularly and individualized based on the needs of each person, considering options such as automated insulin delivery, inhaled insulin, or multiple daily injections. This manuscript reviews the causes and contributors of postprandial hyperglycemia and strategies for its management. In particular, use of lifestyle management, insulin dose adjustments, timing of premeal insulin doses, and insulin kinetics will be reviewed for precision management of postprandial hyperglycemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.